eli lilly

Lilly And Ceptyr Announce Drug Discovery Collaboration

Eli Lilly and Company and Ceptyr, Inc., have announced a two-year research collaboration for the discovery of small molecules to treat diabetes, obesity, and impaired glucose tolerance. The collaboration will focus on the phosphatase target, PTP1B, using Ceptyr’s proprietary assays and screening technology. Ceptyr will receive an upfront signing fee, research funding, milestone payments and Read more about Lilly And Ceptyr Announce Drug Discovery Collaboration[…]

eli lilly

Eli Lilly And Reliant Announce Sales And Marketing Agreement

Reliant Pharmaceuticals, LLC, and Eli Lilly and Company announced that Lilly would sell to Reliant the sales and marketing rights for the antiulcer agent Axid in the United States (excluding Puerto Rico). This agreement will help maximize future sales of Axid through expanded sales and marketing efforts and the development of additional formulations by Reliant. Read more about Eli Lilly And Reliant Announce Sales And Marketing Agreement[…]

Ligand Pharmaceuticals

Ligand, Lilly Agree Second Extension To R&D Collaboration

Ligand Pharmaceuticals and Eli Lilly and Company will extend until November 2004 their research collaboration focused on discovering novel drugs for type II diabetes and cardiovascular disorders. This represents the second extension of the collaboration with Lilly, and further strengthens both partners’ confidence in continued success going forward. The Lilly-Ligand collaboration, which began in 1997, Read more about Ligand, Lilly Agree Second Extension To R&D Collaboration[…]

TransForm Pharmaceuticals

TransForm Earns Performance Milestone In Lilly Collaboration

TransForm Pharmaceuticals, Inc. has received a $1 million performance milestone payment from its partner, Eli Lilly and Company, under their collaboration. The performance payment was contingent on TransForm attaining several critical success factors by the end of 2002 as outlined in the agreement. TransForm and Lilly entered into their multi-year collaboration earlier in 2002 to Read more about TransForm Earns Performance Milestone In Lilly Collaboration[…]

eli lilly

Applied Molecular Evolution, Lilly Agree Second Collaboration

Applied Molecular Evolution Inc. (AME) has agreed to optimize an additional therapeutic antibody candidate for Eli Lilly and Co. In December 2001 AME announced its initial collaboration to optimize an antibody and a non-antibody protein therapeutic for Lilly. The goal of the current collaboration is to apply AME‘s proprietary AMEsystem directed molecular evolution technology to Read more about Applied Molecular Evolution, Lilly Agree Second Collaboration[…]

Isis, Lilly Expand Collaboration Into Cancer Drugs

Isis Pharmaceuticals Inc. and Eli Lilly and Co. have expanded their collaboration to develop cancer drugs based on a technology known as antisense. Isis, a small biotechnology company based in Carlsbad, California, and drug giant Lilly, based in Indianapolis, said they had formed a two-year collaboration to discover drugs associated with specific genes that the Read more about Isis, Lilly Expand Collaboration Into Cancer Drugs[…]

Ligand Pharmaceuticals

Ligand And Lilly Advance Novel Drugs

Ligand Pharmaceuticals Incorporated has announced that LY510929, a novel PPAR agonist, and a back-up compound have been declared clinical candidates for development as novel oral treatments for type 2 diabetes and cardiovascular disease. Ligand expects an Investigational New Drug Application (IND) to be filed with the FDA for LY510929 or the back-up compound in the Read more about Ligand And Lilly Advance Novel Drugs[…]

eli lilly

Millennium And Lilly Extend Collaboration

Millennium Pharmaceuticals, Inc. and Eli Lilly and Company have announced a one-year extension of their cardiovascular disease research collaboration. The five-year partnership, originally due to expire in October, will continue at full capacity at least through October of 2001, at which time Lilly has the option to extend for up to two additional years. Since Read more about Millennium And Lilly Extend Collaboration[…]

(R)-Fluoxetine License Agreement To Become Effective

Sepracor Inc. has announced that the Federal Trade Commission (FTC) has closed its investigation, under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act, of the license agreement that allows Eli Lilly and Company to exclusively develop and globally commercialize (R) – fluoxetine. (R)-Fluoxetine, a new chemical entity, is a modified form of an active ingredient found in Read more about (R)-Fluoxetine License Agreement To Become Effective[…]